# Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients

> **NCT04965935** · PHASE3 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 52 (actual)

## Conditions studied

- Kidney Transplant Recipients
- Post-transplant Diabetes Mellitus
- Type 2 Diabetes

## Interventions

- **DRUG:** Dapagliflozin 10 MG Oral Tablet
- **DRUG:** Placebo Matching Dapagliflozin Oral Tablet

## Key facts

- **NCT ID:** NCT04965935
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-15
- **Primary completion:** 2024-08-30
- **Final completion:** 2024-08-30
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04965935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04965935, "Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04965935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*